Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. André T, et al. Among authors: hug de larauze m. J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620995 Clinical Trial.
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup. Lapeyre-Prost A, et al. Among authors: hug de larauze m. Clin Colorectal Cancer. 2016 Sep;15(3):250-6. doi: 10.1016/j.clcc.2015.11.004. Epub 2015 Dec 2. Clin Colorectal Cancer. 2016. PMID: 26752558 Free article.
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Hamidou Z, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol ML, de Gramont A, Bonnetain F. Hamidou Z, et al. Among authors: hug de larauze m. PLoS One. 2016 Jun 16;11(6):e0157067. doi: 10.1371/journal.pone.0157067. eCollection 2016. PLoS One. 2016. PMID: 27310205 Free PMC article. Clinical Trial.
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, Dumont S, Louvet C, Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. Diouf M, et al. Among authors: hug de larauze m. Health Qual Life Outcomes. 2014 May 13;12:69. doi: 10.1186/1477-7525-12-69. Health Qual Life Outcomes. 2014. PMID: 24886671 Free PMC article. Clinical Trial.